Sopharma AD-SofiaXBUL:SFA -0.26%59 3-Year Revenue Growth Rate is -16.90% as of Mar. 2026. GuruFocus rates XBUL:SFA with a GF Score™ of 59/100 and a GF Value™ of €3.17 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 114 Medical Distribution companies, Sopharma AD-Sofia ranks worse than 89.47% on this metric.
During the past 12 months, Sopharma AD-Sofia's average Revenue per Share Growth Rate was -40.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -16.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -5.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 5.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Sopharma AD-Sofia was 14.00% per year. The lowest was -16.90% per year. And the median was 8.70% per year.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Sopharma AD-Sofia 3-Year Revenue Growth Rate Related Terms
XBUL:SFA vs MCK, COR, CAH: 3-Year Revenue Growth Rate Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia 3-Year Revenue Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of -16.90% mean?
Sopharma AD-Sofia (XBUL:SFA) has a 3-Year Revenue Growth Rate of -16.90% as of Mar. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Sopharma AD-Sofia and its competitors. According to the industry distribution chart, Sopharma AD-Sofia ranks #102 out of 114 companies in the Medical Distribution industry, placing it in the top 89.5%.
Is Sopharma AD-Sofia's 3-Year Revenue Growth Rate too high?
Sopharma AD-Sofia's current 3-Year Revenue Growth Rate is -16.90%. Based on the distribution chart, Sopharma AD-Sofia ranks #102 out of 114 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sopharma AD-Sofia has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's 3-Year Revenue Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #102 out of 114 companies for 3-Year Revenue Growth Rate. This places Sopharma AD-Sofia in the lower half of its industry. The industry median 3-Year Revenue Growth Rate is 5.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Medical Distribution company?
The median 3-Year Revenue Growth Rate among Medical Distribution companies is 5.05, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median 3-Year Revenue Growth Rate is 5.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current 3-Year Revenue Growth Rate is -16.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (XBUL:SFA) is currently considered Possible Value Trap. The stock's GF Value™ is €3.17, compared to a current price of €1.94 — trading 39% below its estimated fair value. The current 3-Year Revenue Growth Rate is -16.90%. Sopharma AD-Sofia's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Sopharma AD-Sofia (XBUL:SFA), the current 3-Year Revenue Growth Rate is -16.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (XBUL:SFA) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of €1.94 is trading 39% below its estimated GF Value™ of €3.17.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for XBUL:SFA:
3-Year Revenue Growth Rate: -16.90%
GF Value™: €3.17 vs. price of €1.94 (39% below fair value)
No single metric tells the full story. See the XBUL:SFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
59GF Score
Get the complete analysis for XBUL:SFA
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:SFA has been successfully added to your 